Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritis.
Adult
Axons
/ pathology
Disease Progression
Evoked Potentials, Visual
/ physiology
Female
Humans
Longitudinal Studies
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
/ pathology
Myelin Sheath
/ pathology
Optic Nerve
/ pathology
Optic Neuritis
/ pathology
Retinal Ganglion Cells
/ pathology
Tomography, Optical Coherence
Visual Pathways
/ pathology
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
07
10
2019
accepted:
30
01
2020
entrez:
15
3
2020
pubmed:
15
3
2020
medline:
3
8
2021
Statut:
epublish
Résumé
To examine the effect of chronic demyelination in the optic nerve of patients with MS on progressive loss of retinal ganglion cell (RGC) axons. Progressive retinal nerve fiber layer (RNFL) loss, as measured by optical coherence tomography, was longitudinally examined in 51 patients with MS with a history of unilateral optic neuritis (ON) and 25 normal controls. Patients were examined annually with a median of 4-year follow-up. Pairwise intereye comparison was performed between ON and fellow non-ON (NON) eyes of patients with MS using the linear mixed-effects model and survival analysis. The latency asymmetry of multifocal visual evoked potential (mfVEP) was used to determine the level of demyelination in the optic nerve. Although both ON and NON eyes demonstrate significantly faster loss of RGC axons compared with normal subjects, ON eyes with severe chronic demyelination show accelerated thinning in the RNFL in the temporal sector of the optic disc (temporal RNFL [tRNFL]) compared with fellow eyes (evidenced by both the linear mixed-effects model and survival analysis). Furthermore, progressive tRNFL thinning is associated with the degree of optic nerve demyelination and reflects the topography of pathology in the optic nerve. More rapid axonal loss in ON eyes is also functionally evidenced by mfVEP amplitude reduction, which correlates with the level of optic nerve demyelination. Although the effect of demyelination on axonal survival has been demonstrated in experimental studies, our results provide first clinically meaningful evidence that chronic demyelination is associated with progressive axonal loss in human MS.
Identifiants
pubmed: 32170043
pii: 7/3/e700
doi: 10.1212/NXI.0000000000000700
pmc: PMC7136042
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Br J Ophthalmol. 2009 Jun;93(6):775-81
pubmed: 19304586
Ann Clin Transl Neurol. 2018 Oct 24;5(12):1505-1512
pubmed: 30564617
Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10 Pt 2):35-41
pubmed: 28139609
Invest Ophthalmol Vis Sci. 2012 Jun 20;53(7):3662
pubmed: 22723598
Ann Neurol. 2018 Feb;83(2):208-209
pubmed: 29328526
Invest Ophthalmol Vis Sci. 2010 May;51(5):2770-7
pubmed: 20042660
Invest Ophthalmol Vis Sci. 2012 Mar 15;53(3):1473-8
pubmed: 22297498
CNS Drugs. 2018 Dec;32(12):1159-1171
pubmed: 30267385
J Glaucoma. 2015 Jun-Jul;24(5):e109-15
pubmed: 25517254
Neurol Neuroimmunol Neuroinflamm. 2019 Jul 16;6(5):
pubmed: 31454773
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):692-8
pubmed: 17251467
Neurobiol Aging. 2012 Feb;33(2):428.e7-19
pubmed: 21190758
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2311-7
pubmed: 27127930
Neurology. 2014 Jun 17;82(24):2165-72
pubmed: 24838786
Nat Rev Drug Discov. 2017 Sep;16(9):617-634
pubmed: 28685761
PLoS One. 2015 May 28;10(5):e0121084
pubmed: 26020925
PLoS One. 2012;7(4):e34823
pubmed: 22536333
Brain. 2019 Feb 1;142(2):426-442
pubmed: 30668642
eNeuro. 2018 Apr 6;5(1):
pubmed: 29662941
Lancet Neurol. 2010 Sep;9(9):921-32
pubmed: 20723847
N Engl J Med. 1998 Jan 29;338(5):278-85
pubmed: 9445407
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1069-1075
pubmed: 30897622
Br J Ophthalmol. 2011 Nov;95(11):1577-82
pubmed: 21785155
J Neurosci. 2003 Jun 15;23(12):4967-74
pubmed: 12832519
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Mult Scler Relat Disord. 2018 Apr;21:56-62
pubmed: 29459346
Ophthalmology. 2017 May;124(5):688-696
pubmed: 28187977
Lancet Neurol. 2016 May;15(6):574-84
pubmed: 27011339
Invest Ophthalmol Vis Sci. 1998 May;39(6):937-50
pubmed: 9579473
Nature. 2010 Nov 11;468(7321):244-52
pubmed: 21068833
Ann Neurol. 2010 Jun;67(6):749-60
pubmed: 20517936
Invest Ophthalmol Vis Sci. 2011 Aug 29;52(9):6911-8
pubmed: 21791585
Lancet Neurol. 2017 Oct;16(10):797-812
pubmed: 28920886
Am J Pathol. 2000 Jul;157(1):267-76
pubmed: 10880396
Ophthalmology. 2019 Mar;126(3):445-453
pubmed: 30060979
Neurology. 2016 Jun 14;86(24):2303-9
pubmed: 27225223
Brain. 2010 Jun;133(Pt 6):1591-601
pubmed: 20410146
PLoS One. 2016 Oct 5;11(10):e0163774
pubmed: 27706215
Neurol Neuroimmunol Neuroinflamm. 2017 Dec 15;5(1):e427
pubmed: 29259999
Eur J Neurol. 2017 Nov;24(11):1392-1398
pubmed: 28799222